Role of antiviral therapy in the management of hepatocellular carcinoma

Anti-Cancer Drugs

Volumn 24, Issue 4, 2013, Pages 337-343

  Guan, Yong Song ^a   He, Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

antiviral; hepatocellular carcinoma; recurrence; therapy

Indexed keywords

ADEFOVIR; ANTIFIBROTIC AGENT; BOCEPREVIR; CURCUMIN; ENTECAVIR; INTERFERON; LAMIVUDINE; MICRORNA; PEGINTERFERON; PHYLLANTHUS AMARUS EXTRACT; PROTEINASE INHIBITOR; RIBAVIRIN; SILYMARIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR; TURMERIC;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; CANCER RECURRENCE; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA INTERFERENCE; SURVIVAL RATE; TUMOR ABLATION; VIRUS REPLICATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; CELL TRANSFORMATION, VIRAL; COMBINED MODALITY THERAPY; COMPLEMENTARY THERAPIES; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATECTOMY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; RECURRENCE; TUMOR VIRUS INFECTIONS; VIRUS INTEGRATION;

EID: 84875054490     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835ec39a     Document Type: Review

References (106)

1. Chae HB, Hann HW. Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection. Ther Clin Risk Manag 2007; 3:605-612
2. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011; 81 (Suppl 1):50-55
3. Xi T, ECh Lai, Min AR, Shi LH, Wu D, Xue F, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: A non-randomized comparative study. Hepatogastroenterology 2012; 59:1198-1203
4. Riaz M, Idrees M, Kanwal H, Kabir F. An overview of triple infection with hepatitis B, C and D viruses. Virol J 2011; 8:368
5. Vlaar AP, Rietdijk ST, Zeerleder SS, Boerman T, Beuers U. Malignancies associated with chronic hepatitis C: Case report and review of the literature. Neth J Med 2011; 69:211-215
6. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinomä J Gastroenterol Hepatol 2011; 26:221-227
7. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow. Liver Int 2012; 32 (Suppl 1): 88-102
8. Liu YN, Lou GH, Chen Z. Research advances on treatment of hepatitis C infection based on RNA interference and microRNA modulation. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40:609-616
9. Tolmane I, Rozentale B, Keiss J, Arsa F, Brigis G, Zvaigzne A. The prevalence of viral hepatitis C in Latvia: A population-based study. Medicina (Kaunas) 2011; 47:532-535
10. WHO. Department of Communicable Diseases Surveillance and Response. Hepatitis B. Available at:Http://www.who.int/csr/disease/ hepatitis/HepatitisB- whocdscsrlyo2002-2.pdf
11. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 2010; 15 (Suppl 4):5-13
12. Gańczak M, Bohatyrewicz A, Korzeń M, Karakiewicz B. The comparison of sharps injuries reported by doctors versus nurses from surgical wards in the context of the prevalence of HBV, HCV and HIV infections. Pol Przegl Chir 2012; 84:190-195
13. Urbanus AT, van den Hoek A, Boonstra A, van Houdt R, de Bruijn LJ, Heijman T, et al. People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands. PLoS One 2011; 6:e24736
14. Li Y, Chang SC, Goldstein BY, Scheider WL, Cai L, You NC, et al. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol 2011; 35: 362-368
15. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: A nationwide survey 2006-2008. J Gastrointestin Liver Dis 2010; 19:373-379
16. Ataei B, Tayeri K, Kassaian N, Farajzadegan Z, Babak A. Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: Seroprevalence and associated factors. Hepat Mon 2010; 10: 188-192
17. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005; 3:27
18. Carrenö V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol 2012; 18:2887-2894
19. El-Faramawy AA, El-Rashidy OF, Tawfik PH, Hussein GH. Transfusion transmitted hepatitis: Where do we stand now? A one center study in upper Egypt. Hepat Mon 2012; 12:286-291
20. Daw MA, Dau AA. Hepatitis C virus in the Arab world: A state of concern. Sci World J 2012; 2012:719494
21. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (Suppl 2):30-60
22. Chaudhury S, Perelson AS, Sinitstyn NA. Spontaneous clearance of viral infections by mesoscopic fluctuations. PLoS One 2012; 7:e38549
23. Thomas DL. Advances in the treatment of hepatitis C virus infection. Top Antivir Med 2012; 20:5-10
24. Centers for Disease Control and Prevention (CDC). Notes from the field:Hepatitis C virus infections among young adults - rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:358
25. Centers for Disease Control and Prevention (CDC). Investigation of viral hepatitis infections possibly associated with health-care delivery - New York City, 2008-2011. MMWR Morb Mortal Wkly Rep 2012; 61: 333-338
26. Attaullah S, Khan S, Khan J. Trend of transfusion transmitted infections frequency in blood donors:Provide a road map for its prevention and control. J Transl Med 2012; 10:20
27. Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S,Wiest K, et al. Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness. Addict Behav 2012; 37:552-555
28. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011. pp. 537-541
29. Khan S, Attaullah S, Ali I, Ayaz S, Naseemullah, Khan SN, et al. Rising burden of hepatitis C virus in hemodialysis patients. Virol J 2011; 8:438
30. Zein NN. The epidemiology and natural history of hepatitis C virus infection. Cleve Clin J Med 2003; 70 (Suppl 4):S2-S6
31. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol 2012; 57:736-742
32. Ghadir MR, Belbasi M, Heidari A, Jandagh M, Ahmadi I, Habibinejad H, et al. Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. Hepat Mon 2012; 12:112-117
33. Coles E, Themessl-Huber M, Freeman R. Investigating community-based health and health promotion for homeless people: A mixed methods review. Health Educ Res 2012; 27:624-644
34. Gyarmathy VA, Ujhelyi E, Neaigus A. HIV and selected blood-borne and sexually transmitted infections in a predominantly Roma (gypsy) neighbourhood in Budapest Hungary: A rapid assessment. Cent Eur J Public Health 2008; 16:124-127
35. Gillies M, Palmateer N, Hutchinson S, Ahmed S, Taylor A, Goldberg D. The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: A systematic review. BMC Public Health 2010; 10:721
36. Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364:2199-2207
37. Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararouei M. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med 2012; 15:271-274
38. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: A population-based study. Arch Iran Med 2009; 12:225-231
39. Stein JA, Andersen RM, Robertson M, Gelberg L. Impact of hepatitis B and C infection on health services utilization in homeless adults: A test of the Gelberg-Andersen Behavioral Model for Vulnerable Populations. Health Psychol 2012; 31:20-30
40. Jokhio AH, Bhatti TA, Memon S. Knowledge, attitudes and practices of barbers about hepatitis B and C transmission in Hyderabad, Pakistan. East Mediterr Health J 2010; 16:1079-1084
41. Cho ER, Shin A, Choi KS, Lee HY, Kim J. Factors associated with use of ultrasonography screening for hepatocellular carcinoma among hepatitis B or C carriers. Cancer Epidemiol 2010; 34:713-716
42. Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size:Model validation using US data. Liver Int 2011; 31 (Suppl 2):4-17
43. Garci'a-Fulgueiras A, Garci'a-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: A methodological challenge of an unfolding health problem. J Viral Hepat 2011; 18:e453-e460
44. Flores YN, Lang CM, Salmeró n J, Bastani R. Risk factors for liver disease and associated knowledge and practices among Mexican adults in the US and Mexico. J Community Health 2012; 37:403-411
45. Thein HH,Walter SR, Gidding HF, Amin J, Law MG, George J, et al. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: A population-based cohort study, 1992-2007. J Viral Hepat 2011; 18:e232-e241
46. Jiang X, Pan SY, de Groh M, Liu S, Morrison H. Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis. J Gastrointest Oncol 2011; 2:223-231
47. Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C. Virol J 2012; 9:57
48. Herzer K, Sprinzl MF, Galle PR. Hepatitis viruses: Live and let die. Liver Int 2007; 27:293-301
49. Gurtsevitch VE. Human oncogenic viruses:Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc) 2008; 73:504-513
50. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53:150-157
51. Bridges JF, Joy SM, Gallego G, Kudo M, Ye SL, Han KH, et al. Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev 2011; 12:2585-2591
52. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-1188
53. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian- Americans. J Immigr Minor Health 2011; 13:842-848
54. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol 2010; 9 (Suppl):119-122
55. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis:Incidence and risk factors. Gastroenterology 2004; 127 (Suppl 1):S35-S50
56. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29:2309-2324
57. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42:513-521
58. Tangutur NK, Medvedev SF, Regenstein F, Balart LA. Hepatocellular carcinoma, a rapidly increasing public health problem: The Tulane experience 2003-2009. J La State Med Soc 2011; 163:185-190
59. Grakoui A. Hepatitis C virus infection. How does the host respond? Minerva Gastroenterol Dietol 2004; 50:21-28
60. Horner SM, Gale M Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 2009; 29:489-498
61. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (Suppl 1):S59-S67
62. Caporaso N, Romano M, Marmo R, de Sio I, Morisco F, Minerva A, Coltorti M. Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1991; 12:367-371
63. Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, et al. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist 2011; 16:310-318
64. Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol 2010; 16:4061-4065
65. Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- And hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol 2008; 14:6072-6077
66. Machida K, McNamara G, Cheng KT, Huang J, Wang CH, Comai L, et al. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes. J Immunol 2010; 185:6985-6998
67. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30: 1969-1983
68. Ierardi E, Rosania R, Zotti M, Giorgio F, Prencipe S, Valle ND, et al. From chronic liver disorders to hepatocellular carcinoma:Molecular and genetic pathways. World J Gastrointest Oncol 2010; 2:259-264
69. Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: A systematic review. Curr Genomics 2011; 12:130-137
70. Liu Y, Zhu X, Zhu J, Liao S, Tang Q, Liu K, et al. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep 2007; 18:943-951
71. Yoon SY, Kim JM, Oh JH, Jeon YJ, Lee DS, Kim JH, et al. Gene expression profiling of human HBV- And/or HCV-Associated hepatocellular carcinoma cells using expressed sequence tags. Int J Oncol 2006; 29:315-327
72. Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, et al. Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res 2009; 28:24
73. Li N, Long Y, Fan X, Liu H, Li C, Chen L, et al. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 2009; 28:122
74. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, et al. Inactivation of Ras GTPase-Activating proteins promotes unrestrained activity of wild-Type Ras in human liver cancer. J Hepatol 2011; 54: 311-319
75. Zhang M, Dai C, Zhu H, Chen S, Wu Y, Li Q, et al. Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem 2011; 357 (1-2): 387-395
76. Smith MW, Yue ZN, Geiss GK, Sadovnikova NY, Carter VS, Boix L, et al. Identification of novel tumor markers in hepatitis C virus-Associated hepatocellular carcinoma. Cancer Res 2003; 63:859-864
77. Petrik J, Parker H, Alexander GJ. Human hepatic glyceraldehyde-3- phosphate dehydrogenase binds to the poly(U) tract of the 30 non-coding region of hepatitis C virus genomic RNA. J Gen Virol 1999; 80 (Pt 12):3109-3113
78. Fiore G, Angarano I, Caccetta L, Serrone M, Jirillo E, Schiraldi O, et al. In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C. Eur J Gastroenterol Hepatol 1997; 9:491-496
79. Ghosh S, Ahrens WA, Phatak SU, Hwang S, Schrum LW, Bonkovsky HL. Association of filamin A and vimentin with hepatitis C virus proteins in infected human hepatocytes. J Viral Hepat 2011; 18:e568-e577
80. Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol 2002; 67:454-457
81. Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, et al. Innate host response in primary human hepatocytes with hepatitis C virus infection. PLoS One 2011; 6:e27552
82. Kim W, Oe Lim S, Kim JS, Ryu YH, Byeon JY, Kim HJ, et al. Comparison of proteome between hepatitis B virus- And hepatitis C virus-Associated hepatocellular carcinoma. Clin Cancer Res 2003; 9:5493-5500
83. Khattab MA, Eslam M, Mousa YI, Ela-Adawy N, Fathy S, Shatat M, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol 2012; 11:487-494
84. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273
85. Li S, Vriend LE, Nasser IA, Popov Y, Afdhal NH, Koziel MJ, et al. Hepatitis C virus-specific T cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Hepatology 2012; 56:2094-2105
86. Deuffic-Burban S. Expected increase in prevalence of HCV-related cirrhosis and its complications in the United States: No effect of current antiviral treatment coverage? Gastroenterol Clin Biol 2010; 34:577-579
87. Loo NM, Pryce DJ. Exploring hepatitis B: A neglected disease. Minn Med 2012; 95:37-40
88. Irving WL. Acute hepatitis C virus infection: A neglected disease? Gut 2006; 55:1075-1077
89. Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011; 35:813-818
90. Fateen AA, Shahin RY, Farres MN, Eldeeb MA, Amer HA. Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. Ann Hepatol 2012; 11:464-470
91. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004; 11:18-25
92. Szabó E, Páska C, Kaposi Nová k P, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res 2004; 10:5-11
93. Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int 2012; 25:192-200
94. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-Analysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33:1104-1112
95. Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: A prospective cohort study. Eur J Surg Oncol 2012; 38:683-691
96. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007; 133: 1649-1659
97. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic hepatitis C treatment outcomes in low- And middle-income countries: A systematic review and meta-Analysis. Bull World Health Organ 2012; 90:540-550
98. Fox AN, Jacobson IM. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. Clin Infect Dis 2012; 55 (Suppl 1):S16-S24
99. Baha W, Ennaji MM, Lazar F, Melloul M, El Fahime E, El Malki A, et al. HBV genotypes prevalence, precore and basal core mutants in Morocco. Infect Genet Evol 2012; 12:1157-1162
100. Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update. J Gastroenterol Hepatol 2011; 26:829-835
101. Kondo M, Kitada N, Kobayashi M, Morita S, Yoshioka M, Tsuji T, et al. A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma. Gan To Kagaku Ryoho 2009; 36:1199-1201
102. Ha HL, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol 2010; 16:6035-6043
103. Bühler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32 (Suppl 1):9-16
104. Keck K, Volper EM, Spengler RM, Long DD, Chan CY, Ding Y, et al. Rational design leads to more potent RNA interference against hepatitis B virus: Factors effecting silencing efficiency. Mol Ther 2009; 17:538-547
105. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45:355-360
106. Ivacik D, Ely A, Arbuthnot P. Countering hepatitis B virus infection using RNAi:How far are we from the clinic? Rev Med Virol 2011; 21:383-396